Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment Study.
Journal: Plastic and reconstructive surgery
Published: December 02, 2025
OnabotulinumtoxinA for Platysma Prominence: Safety and Efficacy Results from a Phase 3 Open-Label Repeat Treatment Study.
Journal: Plastic and reconstructive surgery
Published: December 02, 2025
Longitudinal Computed Tomographic Evaluation of Mandibular Bone Morphology Following OnabotulinumtoxinA Treatment of Masseter Muscle Prominence: Results of a 12-Month, Repeat-Treatment, Placebo-Controlled Study in Healthy Adults.
Journal: Aesthetic surgery journal
Published: August 29, 2025
Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 3-year results from the open-label extension of the randomised controlled phase 3 SELECT-PsA 2 study.
Journal: Clinical and experimental rheumatology
Published: February 23, 2023
Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials.
Journal: Rheumatology and therapy
Published: October 26, 2021
Upadacitinib as monotherapy and in combination with non-biologic disease-modifying antirheumatic drugs for psoriatic arthritis.
Journal: Rheumatology (Oxford, England)
Published: September 02, 2021
Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Journal: Rheumatology and therapy
Published: February 05, 2021
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2.
Journal: Annals of the rheumatic diseases
Published: August 13, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026